648 related articles for article (PubMed ID: 31087644)
1. Intratumoral regulatory T cells: markers, subsets and their impact on anti-tumor immunity.
Yano H; Andrews LP; Workman CJ; Vignali DAA
Immunology; 2019 Jul; 157(3):232-247. PubMed ID: 31087644
[TBL] [Abstract][Full Text] [Related]
2. Regulation of regulatory T cells in cancer.
Stockis J; Roychoudhuri R; Halim TYF
Immunology; 2019 Jul; 157(3):219-231. PubMed ID: 31032905
[TBL] [Abstract][Full Text] [Related]
3. Remodeling of the tumor microenvironment via disrupting Blimp1
Dixon ML; Luo L; Ghosh S; Grimes JM; Leavenworth JD; Leavenworth JW
Mol Cancer; 2021 Nov; 20(1):150. PubMed ID: 34798898
[TBL] [Abstract][Full Text] [Related]
4. Unlocking the Complexities of Tumor-Associated Regulatory T Cells.
Chao JL; Savage PA
J Immunol; 2018 Jan; 200(2):415-421. PubMed ID: 29311383
[TBL] [Abstract][Full Text] [Related]
5. Tumor microenvironment dictates regulatory T cell phenotype: Upregulated immune checkpoints reinforce suppressive function.
Kim HR; Park HJ; Son J; Lee JG; Chung KY; Cho NH; Shim HS; Park S; Kim G; In Yoon H; Kim HG; Jung YW; Cho BC; Park SY; Rha SY; Ha SJ
J Immunother Cancer; 2019 Dec; 7(1):339. PubMed ID: 31801611
[TBL] [Abstract][Full Text] [Related]
6. CD8
Farhood B; Najafi M; Mortezaee K
J Cell Physiol; 2019 Jun; 234(6):8509-8521. PubMed ID: 30520029
[TBL] [Abstract][Full Text] [Related]
7. CD36-mediated metabolic adaptation supports regulatory T cell survival and function in tumors.
Wang H; Franco F; Tsui YC; Xie X; Trefny MP; Zappasodi R; Mohmood SR; Fernández-García J; Tsai CH; Schulze I; Picard F; Meylan E; Silverstein R; Goldberg I; Fendt SM; Wolchok JD; Merghoub T; Jandus C; Zippelius A; Ho PC
Nat Immunol; 2020 Mar; 21(3):298-308. PubMed ID: 32066953
[TBL] [Abstract][Full Text] [Related]
8. Treg-cell depletion promotes chemokine production and accumulation of CXCR3(+) conventional T cells in intestinal tumors.
Akeus P; Langenes V; Kristensen J; von Mentzer A; Sparwasser T; Raghavan S; Quiding-Järbrink M
Eur J Immunol; 2015 Jun; 45(6):1654-66. PubMed ID: 25754875
[TBL] [Abstract][Full Text] [Related]
9. Treg Fragility: A Prerequisite for Effective Antitumor Immunity?
Overacre-Delgoffe AE; Vignali DAA
Cancer Immunol Res; 2018 Aug; 6(8):882-887. PubMed ID: 30068755
[TBL] [Abstract][Full Text] [Related]
10. Targeting regulatory T cells in tumors.
Liu C; Workman CJ; Vignali DA
FEBS J; 2016 Jul; 283(14):2731-48. PubMed ID: 26787424
[TBL] [Abstract][Full Text] [Related]
11. A comprehensive review on the role of co-signaling receptors and Treg homeostasis in autoimmunity and tumor immunity.
Kumar P; Bhattacharya P; Prabhakar BS
J Autoimmun; 2018 Dec; 95():77-99. PubMed ID: 30174217
[TBL] [Abstract][Full Text] [Related]
12. Treg programming and therapeutic reprogramming in cancer.
Moreno Ayala MA; Li Z; DuPage M
Immunology; 2019 Jul; 157(3):198-209. PubMed ID: 30866047
[TBL] [Abstract][Full Text] [Related]
13. Expression of costimulatory and inhibitory receptors in FoxP3
Toker A; Ohashi PS
Adv Cancer Res; 2019; 144():193-261. PubMed ID: 31349899
[TBL] [Abstract][Full Text] [Related]
14. Anti-CTLA-4 Activates Intratumoral NK Cells and Combined with IL15/IL15Rα Complexes Enhances Tumor Control.
Sanseviero E; O'Brien EM; Karras JR; Shabaneh TB; Aksoy BA; Xu W; Zheng C; Yin X; Xu X; Karakousis GC; Amaravadi RK; Nam B; Turk MJ; Hammerbacher J; Rubinstein MP; Schuchter LM; Mitchell TC; Liu Q; Stone EL
Cancer Immunol Res; 2019 Aug; 7(8):1371-1380. PubMed ID: 31239316
[TBL] [Abstract][Full Text] [Related]
15. Stereotactic Radiotherapy Increases Functionally Suppressive Regulatory T Cells in the Tumor Microenvironment.
Muroyama Y; Nirschl TR; Kochel CM; Lopez-Bujanda Z; Theodros D; Mao W; Carrera-Haro MA; Ghasemzadeh A; Marciscano AE; Velarde E; Tam AJ; Thoburn CJ; Uddin M; Meeker AK; Anders RA; Pardoll DM; Drake CG
Cancer Immunol Res; 2017 Nov; 5(11):992-1004. PubMed ID: 28970196
[TBL] [Abstract][Full Text] [Related]
16. Regulatory T Cells in Autoimmunity and Cancer: A Duplicitous Lifestyle.
Hatzioannou A; Boumpas A; Papadopoulou M; Papafragkos I; Varveri A; Alissafi T; Verginis P
Front Immunol; 2021; 12():731947. PubMed ID: 34539668
[TBL] [Abstract][Full Text] [Related]
17. Cancer immunotherapy with check point inhibitor can cause autoimmune adverse events due to loss of Treg homeostasis.
Kumar P; Saini S; Prabhakar BS
Semin Cancer Biol; 2020 Aug; 64():29-35. PubMed ID: 30716481
[TBL] [Abstract][Full Text] [Related]
18. Metabolic Regulation of Tregs in Cancer: Opportunities for Immunotherapy.
Wang H; Franco F; Ho PC
Trends Cancer; 2017 Aug; 3(8):583-592. PubMed ID: 28780935
[TBL] [Abstract][Full Text] [Related]
19. Regulatory T Cells in Ovarian Cancer Are Characterized by a Highly Activated Phenotype Distinct from that in Melanoma.
Toker A; Nguyen LT; Stone SC; Yang SYC; Katz SR; Shaw PA; Clarke BA; Ghazarian D; Al-Habeeb A; Easson A; Leong WL; McCready DR; Reedijk M; Guidos CJ; Pugh TJ; Bernardini MQ; Ohashi PS
Clin Cancer Res; 2018 Nov; 24(22):5685-5696. PubMed ID: 30065096
[No Abstract] [Full Text] [Related]
20. Tumor infiltrating regulatory T cells: tractable targets for immunotherapy.
Khan AR; Dovedi SJ; Wilkinson RW; Pritchard DI
Int Rev Immunol; 2010 Oct; 29(5):461-84. PubMed ID: 20839911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
